Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2014

View Archived Issues

Sosei subsidiary to commence development of two ophthalmic products

Universite de Montreal receives grant from Quebec government for drug development

Regeneron initiates phase I study of intravitreal REGN-2176-3 for wet AMD

Inhibition of protein kinase-induced gene expression is protective against influenza virus infection

Bayer initiates new phase III study of rivaroxaban within EINSTEIN program

GSK researchers present data on novel LSD1 inhibitors

Biomarker-driven development of resminostat

Russian group claims new peptide-based compounds for Abeta accumulation

Galapagos completes recruitment in phase II GLPG-0974 trial

Last patient treated in phase III CicloMulsion study

AXIN2 gene as a potential new biomarker for prostate cancer recurrence

Novartis acquires CoStim Pharmaceuticals

HIV vaccine obtains FDA orphan drug status for pediatric HIV/AIDS infection

Canadian researchers design novel MAbs to human GnRH receptor

Bristol-Myers Squibb divulges novel agents for thromboembolic disorders

FDA grants orphan drug status to rosuvastatin calcium in pediatric HoFH

American and Chinese researchers synthesize novel agents for cancer

Cellectis and Servier enter collaboration to develop allogeneic cell therapies for cancer

Sunshine Biopharma builds mouse models to test Adva-27a in pancreatic cancer

Achelios Therapeutics to begin phase Ib study of topical ELS-M11 for migraine

National Comprehensive Cancer Network recommends Yondelis in trials of uterine leiomyosarcoma

DBV Technologies and Mount Sinai enter collaboration to develop Viaskin for Crohn's disease

Phase III trial of Bayer's long-acting, site-specific recombinant factor VIII meets primary endpoint

Daiichi Sankyo and UMN Pharma form research collaboration to develop norovirus vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...